Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Marwyn Value Investors (MVI) AI Stock Analysis

GB:MVI

Marwyn Value Investors

(LSE:MVI)

Select Model
Rating:83.2Outperform
Price Target:GBX 167.00â–²(17.61% Upside)
Action:reiterated
Date:10/02/26

The overall score is driven primarily by very strong profitability, a conservative, equity-funded balance sheet, and positive cash generation, which together signal robust underlying financial health. A very low P/E and high dividend yield further enhance the appeal, suggesting the shares are undervalued relative to current earnings and distributions. These strengths are tempered by signs of stretched technical momentum and softening free cash flow growth, which increase the risk of near-term price consolidation and raise questions about how sustainably high current earnings will translate into future cash.

Positive Factors
Minimal leverageThe exceptionally low debt burden reduces financial risk and preserves flexibility for capital allocation. A largely equity-funded balance sheet should help the company absorb earnings volatility, sustain distributions, and pursue opportunities without material refinancing or interest-cost pressure.
Negative Factors
Recent revenue contractionThe reported negative revenue-growth figure indicates that the company’s top-line trajectory is not consistently expanding. Persistent contraction would limit operating leverage, reduce resources available for reinvestment, and make future earnings growth more reliant on margins or non-revenue factors.

Marwyn Value Investors (MVI) vs. iShares MSCI United Kingdom ETF (EWC)

-5%0%5%10%15%20%25%30%GB:MVI+11.13%EWC+21.27%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
Market Cap
GBP 80.28M
Dividend Yield
6.38%
Average Volume (3M)
59.59K
Price to Earnings (P/E)
3.9
Beta (1Y)
0.21
Revenue Growth
-0.03%
EPS Growth
106.45%
Country
UK
Employees
11
Sector
Financial
Sector Strength
68
Industry
Asset Management

Marwyn Value Investors Business Overview & Revenue Model

Company Description

Marwyn Value Investors Limited dedicates its capital to small and mid-sized enterprises, implementing strategies that include growth financing, leveraged buyouts, sector consolidation, and expansion through acquisitions. The fund also actively seeks...

Marwyn Value Investors Financial Statement Overview

Summary

Financial performance is very strong, with margins close to 100%, a sharp jump in revenue and earnings, and return on equity rising to around 26%, supported by a virtually debt-free balance sheet and consistently positive operating cash flow. These strengths are partly offset by lumpy revenue growth typical of investment vehicles and weakening free cash flow momentum, which introduces some sustainability risk.

Income Statement

86Very Positive

Balance Sheet

82Very Positive

Cash Flow

74Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue-723.48K38.56M18.67M4.87M2.05M19.09M
Gross Profit-723.48K38.55M18.67M4.87M5.03M19.09M
EBITDA23.86M38.55M-18.68M4.87M2.05M19.09M
Net Income20.62M38.55M18.67M4.86M2.05M19.09M
Balance Sheet
Total Assets142.80M148.56M115.03M101.38M102.42M105.40M
Cash, Cash Equivalents and Short-Term Investments144.97K143.50K140.04K133.99K129.15K128.55K
Total Debt125.00K125.00K125.00K125.00K125.00K125.00K
Total Liabilities144.97K143.50K140.04K133.99K125.00K125.00K
Stockholders Equity142.66M148.41M114.89M101.24M102.29M105.27M
Cash Flow
Free Cash Flow5.03M5.03M5.03M5.91M5.03M11.42M
Operating Cash Flow5.03M5.03M5.03M5.91M5.03M11.42M
Investing Cash Flow000000
Financing Cash Flow-5.03M-5.03M-5.03M-5.91M-5.03M-11.42M

Marwyn Value Investors Peers Comparison

Overall Rating

UnderperformOutperform
Sector (68)

Financial Indicators

GB:MVI against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
GB:MVIGB:MVI83OutperformGBP 79.31M3.9214.17%6.38%-0.03%106.45%
Sector *68Neutral$18.00B11.429.92%3.81%9.73%1.22%
GB:MAFLGB:MAFL62NeutralGBP 15.19M4.1723.41%―543.02%30.22%
GB:PRIMGB:PRIM40UnderperformGBP 4.22M3.1222.69%―――
GB:TRUEGB:TRUE38UnderperformGBP 1.77M-4.09-17.10%――68.42%

* Financial Sector Average

Performance Comparison

0%25%50%75%GB:MVIGB:TRUEGB:MAFLGB:PRIMDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
GB:MVI and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
GB:MVIMarwyn Value Investors142.0014.2211.13%
GB:TRUEBraveheart Investment2.250.157.14%
GB:MAFLMineral & Financial Investments39.004.5013.04%
GB:PRIMPrimorus Investments3.40-0.50-12.82%

Marwyn Value Investors Corporate Events

Business Operations and StrategyStock BuybackDividendsFinancial Disclosures

Marwyn Value Investors Posts Interim Results as Portfolio Resets and Delivers Cash Returns

Positive
Sep 30, 2026

Marwyn Value Investors has published unaudited interim results for the six months to 30 June 2026, reporting net assets attributable to ordinary shares of £138.8 million and an ordinary share NAV total return of -2.4% alongside a positive 3.7% t...

Business Operations and StrategyStock BuybackFinancial DisclosuresM&A Transactions

Marwyn Value Investors boosts alignment as portfolio delivers strategic milestones

Positive
Sep 30, 2026

Marwyn Value Investors has reported unaudited interim results for the six months to 30 June 2026, posting net assets attributable to ordinary shares of £138.8 million and a net asset value of 250.1p per share, alongside an ordinary share NAV tot...

Business Operations and StrategyDividends

Marwyn Value Investors Declares August Interim Dividend

Positive
Jul 30, 2026

Marwyn Value Investors Limited has declared an interim dividend of 2.265 pence per ordinary share, scheduled for payment on 28 August 2026 under its ordinary share distribution policy. The ex-dividend date is set for 6 August and the record date for...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 25, 2026